HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.

Abstract
The aim of this study was to examine the relation between cofilin 1 expression and progression-free survival in advanced epithelial ovarian cancer. We performed quantitative reverse transcriptase polymerase chain reaction and immunohistochemical analysis in 78 patients with advanced epithelial ovarian cancer (excluding those with mucinous and clear-cell types). All patients received the standard therapy, including staging laparotomy and adjuvant chemotherapy consisting of carboplatin and paclitaxel. Of 78 samples, RNA from 62 samples was available for reverse transcriptase polymerase chain reaction analysis. We defined cofilin 1 high expression as relative gene expression equal to or higher than the median and low expression as gene expression lower than median. The progression-free survival was longer in cofilin 1 low-expression cases than in high-expression cases (P = .039). Multivariate analysis demonstrated that stage and cofilin 1 expression were significant predictors of progression-free survival. Of the 78 samples, 54 were appropriate for immunohistochemical study. In 35 of those 54 cases, cofilin 1 protein expression was detected. The progression-free survival was longer in cofilin 1 protein-negative cases than in protein-positive cases (P = .042). Expression of cofilin 1 may predict the progression-free survival of patients with advanced epithelial ovarian cancer receiving standard therapy.
AuthorsSadako Nishimura, Hiroshi Tsuda, Fumio Kataoka, Tokuzo Arao, Hiroyuki Nomura, Tatsuyuki Chiyoda, Nobuyuki Susumu, Kazuto Nishio, Daisuke Aoki
JournalHuman pathology (Hum Pathol) Vol. 42 Issue 4 Pg. 516-21 (Apr 2011) ISSN: 1532-8392 [Electronic] United States
PMID21237490 (Publication Type: Journal Article)
CopyrightCopyright © 2011 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • Cofilin 1
  • Carboplatin
  • Paclitaxel
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Biomarkers, Tumor (analysis, metabolism)
  • Carboplatin (administration & dosage)
  • Carcinoma, Ovarian Epithelial
  • Chemotherapy, Adjuvant
  • Cofilin 1 (biosynthesis)
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Laparotomy
  • Microdissection
  • Middle Aged
  • Neoplasm Staging
  • Neoplasms, Glandular and Epithelial (metabolism, mortality, therapy)
  • Ovarian Neoplasms (metabolism, mortality, therapy)
  • Paclitaxel (administration & dosage)
  • Prognosis
  • Proportional Hazards Models
  • Reverse Transcriptase Polymerase Chain Reaction
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: